Drugs Made In Amer Acqutn Stock Price, News & Analysis
Company Description
Drugs Made In Amer Acqutn (NASDAQ: DMAAR) is a publicly traded company in the Blank Checks sector.
DMAAR stock has declined 15.1% over the past year. Shares last traded at $0.0900.
This page provides a comprehensive overview of DMAAR stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Amer Acqutn (DMAAR) stock last traded at $0.0900. Over the past 12 months, the stock has lost 15.1%.
Latest News
SEC Filings
Drugs Made In Amer Acqutn has filed 4 recent SEC filings, including 4 Form 8-K. The most recent filing was submitted on April 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMAAR SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Drugs Made In Amer Acqutn (DMAAR) currently stands at 36.9 thousand shares, up 487.7% from the previous reporting period. Over the past 12 months, short interest has increased by 697.9%.
Days to Cover History
Days to cover for Drugs Made In Amer Acqutn (DMAAR) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 17.9 days.
DMAAR Company Profile & Sector Positioning
Drugs Made In Amer Acqutn (DMAAR) operates in the Blank Checks sector and is listed on the NASDAQ.